# A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat

Source: https://onco.cc/trials/nct06371157/  
OnCo record `nct06371157` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cadonilimab, Lenvatinib in hepatocellular carcinoma, run by Akeso, now recruiting.

## Summary

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT06371157 by Akeso, with 469 participants planned, started 2024-08-02 and due to reach its primary completion in 2025-10-25. Interventions recorded: AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06371157
- Phase: 3
- Setting: A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
- Sponsor: Akeso
- Enrolled: 469

## Sources

- ClinicalTrials.gov NCT06371157: https://clinicaltrials.gov/study/NCT06371157

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06371157.json